{"id":"W4406119971","doi":"10.1200/jco-24-02242","title":"Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Seagen; Pfizer","keywords":"Medicine; Placebo; Internal medicine; Hazard ratio; Lenalidomide; Diffuse large B-cell lymphoma; Clinical endpoint; Gastroenterology; Brentuximab vedotin; Rituximab; Surgery; Oncology; Confidence interval; Lymphoma; Clinical trial; Multiple myeloma; Pathology; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006158645,0.0003718401,0.001432384,0.0002307812,0.0001426288,0.0002778503,0.0004030779,0.000254362,0.00107317],"category_scores_gemma":[0.0004553599,0.0001159476,0.0003964357,0.000184076,0.0002555239,0.0002296039,0.0001647806,0.0006910306,0.0002642527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003227773,"about_ca_system_score_gemma":0.0002310841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002604664,"about_ca_topic_score_gemma":0.0007663508,"domain_scores_codex":[0.9997225,0.0001366677,0.00002446773,0.00003648463,0.00004612899,0.00003375448],"domain_scores_gemma":[0.9998242,0.00004412749,0.00004899743,0.00001305569,0.000009043039,0.00006060758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2653058,0.007939835,0.01600886,0.002119506,0.001496872,0.0009478252,0.0001200943,0.003158455,0.05376382,0.0004586439,0.004516406,0.6441638],"study_design_scores_gemma":[0.3596216,0.4818092,0.09360943,0.0003566912,0.002415624,0.00521192,0.0001348841,0.007228718,0.01769567,0.0008677234,0.03094941,0.00009909301],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729142,0.02290146,0.0008221439,0.0003322501,0.0001649131,0.0003571794,0.0002342828,0.0001609722,0.002112534],"genre_scores_gemma":[0.9946082,0.003386479,0.0006940652,0.0002822344,0.0001165997,0.0001617154,0.0002412981,0.00000572097,0.0005037785],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001432384,"threshold_uncertainty_score":0.003590167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06247366556726609,"score_gpt":0.4445531832436627,"score_spread":0.3820795176763966,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}